Measles-Rubella vaccination campaign

Sreedevi, A.

doi:10.4103/jpgm.jpgm_104_18

Cited by 7 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The MR vaccine has a robust safety and effectiveness profile. Under field conditions, seroconversion is 85% at 9 months and 95% at 12 months or more for measles, and 95% at 9-12 months and more than 99% when given beyond 12 months for rubella [5]. Adverse reactions are generally mild and transient.…”

Section: Immunogenicity Safety and Efficacy Of Mr Vaccinementioning

confidence: 99%

“…Vaccine hesitancy appears to be a global phenomenon and an increase in vaccine preventable disease has been observed in many developed and developing countries. Vaccine hesitancy refers to delay in acceptance or refusal of vaccination despite availability of vaccination services [5] and it is critical to understand this period of indecision. In India, resistance to vaccination was due to ignorance in the past, though currently, the campaign on social media such as WhatsApp-fuels a mix of conspiracy theories, safety concerns, and questions the need for the MR campaign.…”

Section: Vaccine Hesitancy: a Key Challengementioning

confidence: 99%

See 1 more Smart Citation

‘MR Vaccine Campaign in India’ – Get ahead Success

Agarwal¹,

Sengar²,

Gupta³

et al. 2019

SARJAMS

View full text Add to dashboard Cite

India stands at the cusp of yet another public health feat. Having successfully overcome the challenges of diseases like polio, maternal and neonatal tetanus and yaws in the recent past, the country is making confident strides to triumph over measles and rubella. Viral diseases like measles and rubella even continue to flourish. MR (Measles & Rubella)-vaccine is a combination vaccine administered in a 2-dose schedule, offers protection against Measles, and Rubella. The vaccine is widely recommended by WHO and GAVI as a substitute for prevailing vaccination practices against the above mentioned diseases and viruses. Measles Rubella (MR) campaign is being launched in the country covering all children of 9 months to below 15 years of age group. The vaccine has met with positive and some little negative responses, which leads to challenges about the vaccine's safety and the pros and cons of the vaccine was to be evaluated carefully and ultimately time to replace the current measles primary vaccination schedule in the immunization programme first dose in 9 months, second dose in 15 to 18 months. Conclusion: Elimination of Measles and rubella in India will require a sustainable improvement in both commitment and activity of the whole country towards the WHO goals regarding MR vaccine launched into national immunization schedule.

show abstract

Section: Immunogenicity Safety and Efficacy Of Mr Vaccinementioning

confidence: 99%

Section: Vaccine Hesitancy: a Key Challengementioning

confidence: 99%

‘MR Vaccine Campaign in India’ – Get ahead Success

Agarwal¹,

Sengar²,

Gupta³

et al. 2019

SARJAMS

View full text Add to dashboard Cite

show abstract

“…[38][39][40] The disruption to the measles rubella (MR) campaigns conducted in 2018-19 and recent surveys denoting skepticism to COVID-19 vaccination uptake in India further add to the concern with a possible adverse impact on the national universal immunization program (UIP). [41][42][43][44][45][46] Thus, it is essential that a proactive approach to addressing vaccine hesitancy is developed and the COVID-19 vaccine roll out presents the opportune moment to shape and define the approach: which is built on empathy, respect and trust and not just scientific knowledge and theorems. 47,48…”

Section: Vaccine Hesitancy: the Multiple Layers To Itmentioning

confidence: 99%

Addressing vaccine hesitancy: the LEARN approach

Taneja¹

2022

Int J Community Med Public Health

View full text Add to dashboard Cite

Immunization programs today stand at crossroads. Even as COVID vaccine campaigns continue, inequity, concerns and confusion around them seems ever expanding. While vaccine hesitancy in some form or the other has existed since the inception of vaccination, the complex and dynamic world that we live in now has resulted in hesitancy to vaccines become an outcome of myriad interactions that we encounter in our day to day lives. Factors extraneous to health systems are major determinants and it is essentially the culmination of economics, politics, science, and technology impacting human behaviors and emotions which result in a parent, family or a community arrive at the decision of whether to or not to vaccinate. Vaccine hesitancy is on the rise, it is becoming more organized and now is not just a problem of high- income countries. It is imperative that as public health advocates, academicians, policy makers, managers and implementers we recognize it and adopt a non-judgmental and non-partisan approach built on empathy, respect and trust and not just scientific knowledge and theorems to address it. The current paper puts forward a novel approach to address hesitancy, the LEARN approach: and advocates that we need to ‘Listen’ to the voices of concern, ‘Engage’ with all stakeholders, ‘Articulate’ and communicate better in a language which is simple and comprehensible, ‘Reflect’ on what works and what does not and at the same time ‘Negate’ events and episodes which dent confidence in science and promote complacency.

show abstract

“…The whole country will be covered in four phases in eighteen months. All kids matured between nine months and under 15 years will be given a solitary shot of MR inoculation regardless of their past measles/rubella immunization status or measles/rubella illness status 61,62,63 . There is question can India achieve this goal by 2020?…”

Section: Preventive Measures Of Rubella In India: Indianmentioning

confidence: 99%

Untitled

2019

IJPSR

View full text Add to dashboard Cite

Rubella is an eradicable illness on the grounds of immunization against it produces solid protection. The name rubella comes from the Latin language, and it means "little red". In olden times people thought that rubella was a variant of measles. German literature first described it as a separate disease, and hence it was also called "German Measles". People are the main reservoir of the infection. Before inoculation, rubella was endemic around the world, with plagues occurring every 6-9 years. Congenital rubella syndrome (CRS) acquires a very important place in rubella infection since it leads to a highly damaging effect on the health of newborns. It is transmitted to them by their mothers who have acquired this infection. Babies conceived every year with inborn rubella disorder is a disaster. Although, effective vaccination programs against rubella, especially in combination with immunization against measles has led to the eradication of this disease especially in developed countries like United States of America, still it is vital to recollect that having a powerful antibody does not ensure control of sicknessthe immunization must be appropriated to all who require it. This review focused on the history, mechanism of rubella infection, manifestation and preventive measures for rubella in India. Indian government has launched MR vaccination campaign targeting the children of 9-12 year age group. INTRODUCTION: Rubella is an infection that is spread through the air or by close contact in humans. Rubella virus (RV) belongs to the genus rubivirus. It belongs to the family Togaviridae. Rubella virus infection brings about various complications in a human-like maculopapular rash, second rate fever, lymphadenopathy, sore throat and general disquietude 1. Its genetic material consists of positive-stranded sense RNA 2 .

show abstract

Measles-Rubella vaccination campaign

Cited by 7 publications

References 5 publications

‘MR Vaccine Campaign in India’ – Get ahead Success

‘MR Vaccine Campaign in India’ – Get ahead Success

Addressing vaccine hesitancy: the LEARN approach

Untitled

Contact Info

Product

Resources

About